These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 16825030)

  • 21. Sevelamer therapy for pediatric end-stage renal disease.
    Storms LE; Chicella MF; Dice JE
    Pharmacotherapy; 2006 Mar; 26(3):410-3. PubMed ID: 16503722
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Economic evaluation of sevelamer in patients with end-stage renal disease.
    Manns B; Klarenbach S; Lee H; Culleton B; Shrive F; Tonelli M
    Nephrol Dial Transplant; 2007 Oct; 22(10):2867-78. PubMed ID: 17595182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sevelamer worsens metabolic acidosis in hemodialysis patients.
    De Santo NG; Frangiosa A; Anastasio P; Marino A; Correale G; Perna A; Di Stazio E; Stellato D; Santoro D; Di Meglio E; Iacono G; Ciacci C; Savica V; Cirillo M
    J Nephrol; 2006; 19 Suppl 9():S108-14. PubMed ID: 16736432
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
    Hamida FB; Fatma LB; Barbouch S; Kaaroud H; Helal I; Hedri H; Abdallah TB; Maiz HB; Kheder A
    Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Control of hyperphosphatemia among patients with ESRD.
    Coladonato JA
    J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S107-14. PubMed ID: 16251245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sevelamer hydrochloride: an effective phosphate binder in dialyzed children.
    Mahdavi H; Kuizon BD; Gales B; Wang HJ; Elashoff RM; Salusky IB
    Pediatr Nephrol; 2003 Dec; 18(12):1260-4. PubMed ID: 14586677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis.
    Fan S; Ross C; Mitra S; Kalra P; Heaton J; Hunter J; Plone M; Pritchard N
    Nephrol Dial Transplant; 2009 Dec; 24(12):3794-9. PubMed ID: 19666658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial.
    Suki WN;
    J Ren Nutr; 2008 Jan; 18(1):91-8. PubMed ID: 18089452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis.
    Tzanno-Martins C; Biavo BM; Ferreira-Filho O; Ribeiro-Junior E; João-Luiz MV; Degaspari S; Scavone C; Kawamoto E
    Int J Immunopathol Pharmacol; 2014; 27(1):25-35. PubMed ID: 24674676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The use of sevelamer in the treatment of resistant hyperphosphataemia in children with chronic renal disease].
    Runowski D; Jachimiak B; Cieślak-Puchalska A; Pacanowska B; Zimoń T
    Pol Merkur Lekarski; 2009 Apr; 26(154):318-21. PubMed ID: 19580197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcium load during administration of calcium carbonate or sevelamer in individuals with normal renal function.
    Heinrich T; Heidt H; Hafner V; Schmidt-Gayk H; Jenetzky E; Walter-Sack I; Mikus G; Bommer J
    Nephrol Dial Transplant; 2008 Sep; 23(9):2861-7. PubMed ID: 18388122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride.
    Autissier V; Damment SJ; Henderson RA
    J Pharm Sci; 2007 Oct; 96(10):2818-27. PubMed ID: 17497733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Either calcium carbonate or sevelamer decreases urinary oxalate excretion in chronic renal failure patients].
    Caravaca F; Ruiz AB; Escola JM; Hernández Gallego R; Cerezo I; Fernández N; Barroso S; Martín MV
    Nefrologia; 2007; 27(4):466-71. PubMed ID: 17944584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure.
    Chertow GM; Burke SK; Lazarus JM; Stenzel KH; Wombolt D; Goldberg D; Bonventre JV; Slatopolsky E
    Am J Kidney Dis; 1997 Jan; 29(1):66-71. PubMed ID: 9002531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-treatment of dairy and breast milk with sevelamer hydrochloride and sevelamer carbonate to reduce phosphate.
    Raaijmakers R; Houkes LM; Schröder CH; Willems JL; Monnens LA
    Perit Dial Int; 2013; 33(5):565-72. PubMed ID: 23636435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sevelamer hydrochloride use and circulating endotoxin in hemodialysis patients: a pilot cross-sectional study.
    Sun PP; Perianayagam MC; Jaber BL
    J Ren Nutr; 2009 Sep; 19(5):432-8. PubMed ID: 19464926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival in end stage renal disease: calcium carbonate vs. sevelamer.
    Borzecki AM; Lee A; Wang SW; Brenner L; Kazis LE
    J Clin Pharm Ther; 2007 Dec; 32(6):617-24. PubMed ID: 18021340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacologic intervention for vascular calcification].
    Segawa H; Furutani J; Miyamoto K
    Clin Calcium; 2005 Jul; 15(7):149-54. PubMed ID: 15995312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RenaGel, a novel calcium- and aluminium-free phosphate binder, inhibits phosphate absorption in normal volunteers.
    Burke SK; Slatopolsky EA; Goldberg DI
    Nephrol Dial Transplant; 1997 Aug; 12(8):1640-4. PubMed ID: 9269642
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study.
    Spiegel DM; Farmer B; Smits G; Chonchol M
    J Ren Nutr; 2007 Nov; 17(6):416-22. PubMed ID: 17971314
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.